IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 - 89 - 20 00 33 - 33 01
E-Mail: investor@medigene.com

WEITERE IR-NEWS

14.08.2020 - 23:00 | BAWAG P.S.K. Bank für Arbeit und Wirtschaft und Österreichische Postsparkasse Aktiengesellschaft
14.08.2020 - 18:00 | CA Immobilien Anlagen AG
14.08.2020 - 18:00 | CA Immobilien Anlagen AG
pta20191030039
Business news for the stock market

Medigene AG: Medigene participates at upcoming conferences


Martinsried/ Munich (pta039/30.10.2019/22:00) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Medigene's management and/or scientists will be available for one-on-one meetings at these events.

SITC (Society for Immunotherapy of Cancer) 34th Annual Meeting
Date: 6 - 10 November 2019
Location: National Harbor, USA

BIO Europe
Date: 11 - 13 November 2019
Location: Hamburg, Germany

Jefferies London Healthcare Conference
Date: 20 - 21 November 2019
Location: London, UK

Cell Therapy Manufacturing & Gene Therapy Congress
Date: 3 - 6 December 2019
Location: Amsterdam, Netherlands

61st ASH Annual Meeting & Exposition
Date: 7 - 10 December 2019
Location: Orlando, USA

ESMO Immuno-Oncology Congress 2019
Date: 11 - 14 December 2019
Location: Geneva, Switzerland

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Dr Gary Waanders,
Claudia Burmester, Dr Anna Niedl
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg
Germany
contact person: Medigene PR/IR
phone: +49 - 89 - 20 00 33 - 33 01
e-mail: investor@medigene.com
website: www.medigene.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
|
|
98.405 Abonnenten
|
182.196 Meldungen
|
74.591 Pressefotos

BUSINESS

14.08.2020 - 12:30 | pressetext.redaktion
14.08.2020 - 12:00 | XXXLutz KG
14.08.2020 - 11:20 | BürgschaftsBank Berlin
14.08.2020 - 11:00 | retarus GmbH
14.08.2020 - 06:05 | pressetext.redaktion
Top